De novo metastatic hormone-sensitive prostate cancer usually has a dismal prognosis, which has slightly improved in recent years thanks to the introduction of new hormonal agents and …

Prostate cancer treatments paradigms are in continuous evolution, especially in the metastatic setting. In this context, the Genito-Urinary Group of Italian Association of Radiotherapy and …

The treatment of metastatic hormone-sensitive prostate cancer has evolved rapidly, with the emergence of doublet and triplet therapies transforming outcomes. However, these advances …

The advent of more effective treatment combinations for metastatic hormone-sensitive prostate cancer (mHSPC) has been built on successes in therapy development for metastatic, …

This review assesses current evidence and emerging treatment strategies for improved survival among patients with metastatic hormone-sensitive prostate cancer and offers …

Newly presenting or de novo metastatic hormone-sensitive prostate cancer (mHSPC) accounts for 5% to 10% of all prostate cancer (PC) diagnoses, but it is responsible for nearly 50% of PC …

Purpose: Prostate cancer treatments paradigms are in continuous evolution, especially in the metastatic setting. In this context, the Genito-Urinary Group of Italian Association of …

The treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has changed radically in recent years. Androgen deprivation therapy (ADT) alone was for decades the …

Annually, >1.2 million new cases of prostate cancer are diagnosed and global prostate cancer-related deaths exceed 350 000 per annum, making it one of the leading causes of cancer …

Approximately 17% of PC present with de novo metastasis, resulting in a 5-year relative survival rate of 32% in such instance. 1 Metastatic hormone-sensitive prostate cancer (mHSPC) …